Frank Neumann
Corporate Officer/Principal chez KITE PHARMA INC
Profil
Frank Neumann is currently the Head-Clinical Development at Kite Pharma, Inc. He was previously the Vice President & Head-Oncology Clinical Research at bluebird bio, Inc. and the Chief Medical Officer at Verastem, Inc. He holds a doctorate degree from the University of Bonn and Heinrich-Heine-Universität Düsseldorf.
Postes actifs de Frank Neumann
| Sociétés | Poste | Début |
|---|---|---|
| KITE PHARMA INC | Corporate Officer/Principal | 01/01/2021 |
Anciens postes connus de Frank Neumann
| Sociétés | Poste | Fin |
|---|---|---|
| VERASTEM, INC. | Chief Tech/Sci/R&D Officer | 20/01/2021 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | - |
Formation de Frank Neumann
| University of Bonn | Doctorate Degree |
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
